makhana mornings!

A little context. A lot to think about.

BUSINESS. PEOPLE. THE BIGGER PICTURE.

Clarity for a world that doesn’t slow down.

Glenmark’s axitinib launch uses a different generic route

2 minutes

Glenmark’s US axitinib launch illustrates the authorised-generic pathway, and why reference-product sales are not a forecast of revenue or patient savings.

Comparison: an authorised generic uses the brand's existing NDA, while an independently developed generic is approved through an ANDA. Launch alone does not establish patient savings.

Glenmark’s latest US launch is a reminder that not every generic medicine reaches the market through the same route.

On November 16, the company announced axitinib tablets in 1 mg and 5 mg strengths as an authorised generic of Pfizer’s INLYTA. The important word is “authorised”: this is not an announcement of a new, independent generic-drug approval.

The Breakdown: the label changes, the approval route does not

The US Food and Drug Administration describes an authorised generic as the approved branded drug product marketed without the brand name. It may be sold by the brand owner or another company with its permission, under the original New Drug Application, or NDA.

An independently developed generic follows a different process. Its manufacturer submits an Abbreviated New Drug Application, or ANDA, demonstrating the required sameness and bioequivalence to the reference medicine. Bioequivalence concerns how the medicine reaches the site where it works, rather than simply whether its label lists the same ingredient.

That distinction explains why Glenmark’s launch should not be presented as a fresh FDA approval of a separate generic application. It is a commercial launch through an existing regulatory pathway.

Why the sales figure needs a label

Glenmark cited IQVIA data showing approximately $538.4 million in US INLYTA sales for the 12 months ended September 2026. This describes the reference product’s historical sales, not Glenmark’s future revenue, market share or profit.

A market-size figure answers a different question from a business forecast. It does not reveal how much of that demand a new offering will capture, what buyers will pay or how the commercial economics are divided. The release does not disclose launch pricing, exclusivity or expected revenue contribution.

Why This Matters: availability and affordability are separate

An authorised generic may be offered at a lower cost than the branded product, but that possibility is not a verified saving for a particular patient. Glenmark’s announcement contains no patient-level price comparison. A launch headline is therefore not enough to calculate treatment savings.

This differs from the milestone in our Biocon approval-versus-launch explainer. There, the question was when a reported approval could translate into market access. Here, the company reports a launch; the unanswered questions concern its commercial terms and actual uptake.

The Crunch

Read the route before reading the opportunity. Glenmark has announced an authorised-generic launch, not a new independent approval or a guaranteed share of a $538.4 million market. Actual sales and disclosed pricing will tell more than the reference product’s historical turnover.

Related categories: Business & Brands

Leave your thoughts

You might also like…